What is EdiGene?
Established in 2015 and headquartered in Beijing, EdiGene operates at the intersection of advanced molecular biology and clinical medicine. The company leverages cutting-edge genome editing technologies to streamline drug discovery processes and address unmet medical needs. By focusing on the precision modification of genetic material, EdiGene is positioning itself as a leader in the next generation of curative treatments. Its operational model is designed to bridge the gap between laboratory-scale innovation and large-scale clinical application, ensuring that its therapeutic candidates move efficiently through the regulatory and development lifecycle.
How much funding has EdiGene raised?
EdiGene has raised a total of $154.5M across 3 funding rounds:
Series A
$14.5M
Other Financing Round
$11M
Series B
$129M
Series A (2018): $14.5M with participation from WI Harper Group, IDG, Huagai Capital, and Lilly Asia Ventures
Other Financing Round (2019): $11M led by IDG Capital Partners and Lilly Asia Ventures
Series B (2021): $129M supported by BioTrack Capital, Alwin Capital, Sherpa Healthcare Partners, Loyal Valley Capital, Huagai Capital, Kunlun Capital, 3H Health Investment, IDG Capital Partners, Sequoia Capital, and Lilly Asia Ventures
Key Investors in EdiGene
Lilly Asia Ventures
Lilly Asia Ventures is a premier biomedical venture capital firm with a global footprint, dedicated to partnering with entrepreneurs to develop breakthrough products that improve human health.
IDG Capital Partners
IDG Capital is a long-standing investment firm that focuses on driving growth through private equity, venture capital, and strategic mergers and acquisitions.
BioTrack Capital
BioTrack Capital is a specialized healthcare venture firm that focuses on incubating and scaling innovative life science and medtech companies within the Chinese market.
What's next for EdiGene?
With the infusion of capital from its latest financing, EdiGene is well-positioned to scale its clinical trials and expand its research infrastructure. The company is expected to prioritize the advancement of its lead candidates, focusing on therapeutic efficacy and safety profiles that meet global standards. As it transitions into a more mature phase of development, the firm will likely seek to strengthen its intellectual property portfolio and forge additional strategic partnerships to facilitate the commercialization of its genome-editing assets. The focus remains on maintaining its competitive edge in the rapidly evolving biotech landscape while navigating the complexities of international clinical development.
See full EdiGene company page
